Vasodilatory Effect of the Stable Vasoactive Intestinal Peptide Analog RO 25-1553 in Murine and Rat Lungs

Yin, Jun; Wang, Liming; Yin, Ning; Tabuchi, Arata; Kuppe, Hermann; Wolff, Gerhard; Kuebler, Wolfgang M.
September 2013
PLoS ONE;Sep2013, Vol. 8 Issue 9, p1
Academic Journal
Rationale: Stable analogs of vasoactive intestinal peptide (VIP) have been proposed as novel line of therapy in chronic obstructive pulmonary disease (COPD) based on their bronchodilatory and anti-inflammatory effects. We speculated that VIP analogs may provide additional benefits in that they exert vasodilatory properties in the lung, and tested this hypothesis in both ex vivo and in vivo models. Methods: In isolated perfused mouse lungs and in an in vivo rat model, pulmonary blood vessels were preconstricted by hypoxia and hemodynamic changes in response to systemic (ex vivo) or inhaled (in vivo) administration of the cyclic VIP analog RO 25-1553 were determined. Results: In mouse lungs, RO 25-1553 reduced intrinsic vascular resistance at normoxia, and attenuated the increase in pulmonary artery pressure in response to acute hypoxia. Consistently, inhalation of RO 25-1553 (1 mg·mL−1 for 3 min) caused an extensive and sustained (> 60 min) inhibition of the pulmonary arterial pressure increase in response to hypoxia in vivo that was comparable to the effects of inhaled sildenafil. This effect was not attributable to systemic cardiovascular effects of RO 25-1553, but to a lung specific reduction in pulmonary vascular resistance, while cardiac output and systemic arterial hemodynamics remained unaffected. No adverse effects of RO 25-1553 inhalation on pulmonary gas exchange, ventilation-perfusion matching, or lung fluid content were detected. Conclusion: Our findings demonstrate that inhaled delivery of the stable VIP analog RO 25-1553 induces a potent and sustained vasodilatory effect in the pulmonary circulation with no detectable adverse effects. Therapeutic inhalation of RO 25-1553 may provide vascular benefits in addition to its reported anti-inflammatory and bronchodilatory effects in COPD, yet caution is warranted given the overall poor results of vasodilator therapies for pulmonary hypertension secondary to COPD in a series of recent clinical trials.


Related Articles

  • Impaired resolution of inflammatory response in the lungs of JF1/Msf mice following carbon nanoparticle instillation. Ganguly, Koustav; Upadhyay, Swapna; Irmler, Martin; Takenaka, Shinji; Pukelsheim, Katrin; Beckers, Johannes; De Angelis, Martin Hrabé; Hamelmann, Eckard; Stoeger, Tobias; Schulz, Holger // Respiratory Research;Jul2011, Vol. 12 Issue 7, p1 

    Background: Declined lung function is a risk factor for particulate matter associated respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Carbon nanoparticles (CNP) are a prominent component of outdoor air pollution that causes pulmonary toxicity...

  • Tissue Concentrations of Vasoactive Intestinal Peptide Are Affected by Peritonitis-Induced Sepsis and Hemofiltration in Pigs. KUNCOVÁ, J.; CHVOJKA, J.; SÝKORA, R.; ŠVÍGLEROVÁ, J.; ŠTENGL, M.; NALOS, L.; KROUŽECKÝ, A.; MATĔJOVIČ, M. // Physiological Research;2011, Vol. 60 Issue 3, p531 

    Vasoactive intestinal peptide (VIP) is a neuropeptide released from the autonomic nerves exerting multiple antiinflammatory effects. The aim of the present study was to investigate the impact of severe sepsis and hemofiltration in two settings on plasma and tissue concentrations of VIP in a...

  • Vasoactive Intestinal Peptide Enhances TNF-α-Induced IL-6 and IL-8 Synthesis in Human Proximal Renal Tubular Epithelial Cells by NF-κB-Dependent Mechanism. Huang, Ling; Tang, Yiting; Qin, Jiao; Peng, Yu; Yuan, Qiongjing; Zhang, Fangfang; Tao, Lijian // Inflammation;Jun2012, Vol. 35 Issue 3, p1154 

    Vasoactive intestinal polypeptide (VIP) is a 28-amino acid neuropeptide with vasodilator, bronchodilator, and anti-inflammatory effects. But little is known about its pro-inflammatory effects. We investigated the effect of VIP on the secretion of interleukin-6 (IL-6) and interleukin-8 (IL-8),...

  • Epithelial Expression of Vasoactive Intestinal Peptide in Ulcerative Colitis: Down-Regulation in Markedly Inflamed Colon. Jönsson, Maria; Norrgård, Örjan; Forsgren, Sture // Digestive Diseases & Sciences;Feb2012, Vol. 57 Issue 2, p303 

    Background: Vasoactive intestinal peptide (VIP) has a number of important effects in intestinal physiology and pathology, including in ulcerative colitis (UC). The expression patterns of the predominant VIP receptor in the mucosa (the VPAC1 receptor) are unknown for the mucosa in UC. It is...

  • A process-based review of mouse models of pulmonary hypertension. Das, Mita; Fessel, Joshua; Tang, Haiyang; West, James // Pulmonary Circulation;Oct-Dec2012, Vol. 2 Issue 4, p415 

    Genetically modified mouse models have unparalleled power to determine the mechanisms behind different processes involved in the molecular and physiologic etiology of various classes of human pulmonary hypertension (PH). Processes known to be involved in PH for which there are extensive mouse...

  • Guanylin and functional coupling proteins in the hepatobiliary system of rat and guinea pig. Schwabe, Karen; Cetin, Yalcin // Histochemistry & Cell Biology;May2012, Vol. 137 Issue 5, p589 

    Guanylin, a bioactive intestinal peptide, is involved in the cystic fibrosis transmembrane conductance (CFTR)-regulated electrolyte/water secretion in various epithelia. In the present work we report on the expression and cellular localization of guanylin and its affiliated signaling and...

  • The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Vally, H.; Taylor, M. L.; Thompson, P. J. // Thorax;Jul2002, Vol. 57 Issue 7, p569 

    Background: Aspirin intolerant asthma (AIA) is a clinically distinct syndrome characterised by the precipitation of asthma attacks following the ingestion of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). The prevalence of AIA among Australian asthmatic patients...

  • Anoro Ellipta set to change COPD prescribing.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 711 Issue 1, p33 

    The article announces that Anoro Ellipta, a drug used to control and prevent symptoms caused by ongoing lung disease will replace Spiriva, a drug developed by pharmaceutical company C.H. Boehringer Sohn AG & Ko. KG as an effective treatment of chronic obstructive pulmonary disease (COPD).

  • Asthma: Taking Medicines Safely.  // American Family Physician;3/15/2001, Vol. 63 Issue 6, p1217 

    Presents information on the safe way to take medication for patients with asthma. Need for carefulness in taking medicine; Use of aspirin and other pain relievers; Concerns about antihistamines for allergies; Way that certain medication may make asthma symptoms worse.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics